Fig. 4.

Modulation of the Sensitivity to Systemic Amphetamine (2.5 mg/kg, Intraperitoneally) Challenge by Periadolescent Antipsychotic and Antidepressant Drug Treatment in Offspring Born to PolyI:C-Treated and Control (CON) Mothers. The graph illustrates the distance traveled in the open field after nontreatment (bins 1–4), saline (SAL) treatment (bins 5–8), and AMPH treatment (bins 9–24) for CON (a) and PolyI:C offspring (b); the mean distance traveled after AMPH challenge is shown in (c). Periadolescent exposure to haloperidol (HAL) significantly increased basal locomotor activity (ie, after nontreatment and SAL treatment) compared with periadolescent vehicle (VEH) treatment regardless of the prenatal treatment histories. ^#P < .01 between HAL-exposed and VEH-treated subjects, based on Fisher post hoc tests. Prenatal PolyI:C exposure significantly enhanced the locomotor reaction to acute AMPH challenge compared with prenatal CON treatment, ie, VEH-treated PolyI:C offspring displayed an increase in distance traveled in the open field compared with VEH-treated CON offspring following AMPH administration. This effect was attenuated by periadolescent HAL and fluoxetine (FLX) treatment but not by clozapine (CLZ) exposure. In addition, periadolescent HAL treatment (but not CLZ or FLX treatment) potentiated the locomotor reaction to AMPH in CON offspring. *P < .05 between VEH-treated CON offspring and VEH-treated PolyI:C offspring; ⁺P < .05 between HAL-treated and VEH-treated CON offspring; and ^§P < .05 between VEH-treated PolyI:C offspring and HAL- or FLX-treated PolyI:C offspring. The number of subjects in each group is listed in table 1. SED in (a) and (b) refers to twice the standard error of difference derived from the error variance associated with the prenatal treatment × periadolescent treatment × 5-min bins interaction term from the overall ANOVA. All values in (c) are means ± standard error of the mean.